Can-Fite BioPharma Raises $7.2M In Secondary Offering

Can-Fite BioPharma Raises $7.2M In Secondary OfferingIsraeli pharmaceutical company Can-Fite BioPharma Ltd. has announced that it has raised NIS 26.5 million ($7.2 million) in its secondary offering on the Tel Aviv stock exchange. The company says that it will direct the funds towards a phase II/III clinical trial of its psoriasis treatment.